AdvaMed Device Submissions Workshop In Brief
This article was originally published in The Gray Sheet
Executive Summary
New 510(k) paradigm: Level 2 guidance document on 510(k)s is expected to be released by the end of the summer, Office of Device Evaluation Premarket Notification Staff Director Heather Rosecrans tells attendees at AdvaMed's device submissions workshop held June 6-7 in Rockville, Maryland. "We're right at the process of updating the new paradigm, and that's going to go through the GGP [good guidance practices] process. We're going to consider the truthful and accurate...statement in place of the declaration of conformity...with design controls, because there's no end and no beginning and there has been some confusion." Rosecrans highlighted one change for manufacturers submitting 510(k)s: "validation will have to be completed prior to going to market with your device"...
You may also be interested in...
Regulatory News In Brief
Hako-Med petition: Honolulu firm's April 23 petition requesting that low-voltage electrode lead wires in the vacuum hose of the VacuPulls/VasoPulse be exempted from the performance standard for electrode lead wires and patient cables (21 CFR 898) is denied by FDA. "In this instance, the public health derives no benefit from the continued use of non-compliant electrode lead wires that is not already provided by equivalent powered muscle stimulator and powered peripheral nerve stimulator devices that use compliant electrode wires," the agency writes in the Aug. 30 denial letter. "The continued marketing of unprotected electrode leads and patient cables, no matter how they are labeled, presents an unreasonable and substantial risk of illness or injury to individuals"...
Regulatory News In Brief
Hako-Med petition: Honolulu firm's April 23 petition requesting that low-voltage electrode lead wires in the vacuum hose of the VacuPulls/VasoPulse be exempted from the performance standard for electrode lead wires and patient cables (21 CFR 898) is denied by FDA. "In this instance, the public health derives no benefit from the continued use of non-compliant electrode lead wires that is not already provided by equivalent powered muscle stimulator and powered peripheral nerve stimulator devices that use compliant electrode wires," the agency writes in the Aug. 30 denial letter. "The continued marketing of unprotected electrode leads and patient cables, no matter how they are labeled, presents an unreasonable and substantial risk of illness or injury to individuals"...
RAPS In Brief
FDA's James Dillard: Deputy Director Bram Zuckerman will become acting director of FDA's Division of Cardiovascular and Respiratory Devices Dec. 3. Current DCRD Director James Dillard departs Nov. 30 for the private sector, where he has accepted the position of VP-science and technology at U.S. Tobacco. Dillard, a fourteen-year FDA veteran, has held the DCRD position for the last 18 months and overseen the reorganization of the division (1"The Gray Sheet" July 24, 2000, p. 10)...